Clinical Trial Update: Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study [Phase 2]

View source ↗

Summary

A Phase 2 prospective, single-arm multicenter study to evaluate irinotecan liposome II in combination with ivonescimab as second-line therapy for small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Irinotecan Liposome II (irinotecan liposome)
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: The Second Affiliated Hospital of Dalian Medical University | Conditions: SCLC | Phase 2 | Status: NOT_YET_RECRUITING